Join        Login             Stock Quote

BioSante Attracts Institutional Investors Ahead Of Key FDA Catalysts In 2011

 December 28, 2010 10:04 AM

Following the Christmas break, shares of BioSante soared more than 27% during Monday's session on volume of 10.57M shares versus an average of 251,478, leaving investors hungry for the company's potential in its upcoming FDA catalysts in early 2011, as highlighted by our previous article. All seemed well going into the next trading session, that is, until the after-hours session when news of a registered direct offering sparked newly found worries striking fear in the hearts of current and potential shareholders.

To those who follow the biotech industry religiously, this occurrence shouldn't catch anyone off guard, and in most cases does not pose a major roadblock for an undervalued company whose investment purposes should be for the long-haul rather than flipping a few pennies on the dollar. As an immediate example, during the month of December, no less than three highly profiled biotech companies with upcoming catalysts decided to raise cash ahead of these events.

[Related -Automating Ourselves To Unemployment]

These include:

  • EnteroMedics, on December 9th, announced a public offering of $25.9 million at $1.75 per share, at a time when its price was trading at $2.45 per share. The very next trading day, shares popped way past the offering price and moved to $2.20 on heavy volume. Since then, it has gone on to gain a cool 25% while maintaining a steady uptrend. The company expects to medical device study for its product, Maestro System during 2nd half of 2011.
  • Lannett Company, on December 13th, announced a public offering of  5,000,000 shares of its common stock at a price of $5.00 per share. Many expected news of dilution ahead of the pending FDA decision for its flagship product, Morphone Sulfate Oral Solution. Shares dropped initially from its 52-week high peak of $7.00 down to $5.00, yet managed to find solid support and is now rebounding once again with shares now at $5.32 in anticipation of the potential marketability of its product.
  • YM BioSciences, on December 14th, announced a public offering of $40 million at $1.60 per share when its price was trading at $1.80 in the previous session. Since then, the shares have gone on to rally to a new 52-week high of $2.55, and are now up 31% as of today's close to $2.32. The company has a slew of phase 1, 2 and 3 clinical trials which should be reported during 1st half of 2011.

[Related -Fed: Waiting For June… Or Godot?]

It is important to note that in all three of these public offerings, not one of  the companies managed to raise funds from institutional investors, rather opting to simply exchange shares on the open market.

Next Page >>123


Comments Closed

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.